WebDoctor Encyclopedia

Soft-tissue sarcomas

Sclerosing epithelioid fibrosarcoma (SEF)

Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft-tissue sarcoma of adults, made of rounded cells in dense scar-like collagen. It is MUC4-positive, related to low-grade fibromyxoid sarcoma, and often recurs or spreads to the lungs and bone despite slow growth.

Medically reviewed Last reviewed October 19, 2026

What is sclerosing epithelioid fibrosarcoma?

Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft-tissue sarcoma, a cancer of the body’s connective tissue. It usually starts deep in the muscles or fibrous tissue of the thigh, trunk, shoulder or pelvis, and occasionally in bone or internal organs.

Its name describes how it looks under the microscope. The tumour cells are epithelioid (rounded, like lining cells), and they sit in cords and nests within very dense, scar-like collagen, a feature called sclerosis.

SEF was first recognised as a separate tumour in the 1990s. It is now regarded as a close relative of low-grade fibromyxoid sarcoma (LGFMS), and some tumours show features of both. Both types share a marker protein, MUC4, and similar gene fusions (Doyle et al., 2012).

Although SEF often grows slowly and may look harmless at first, it is an aggressive sarcoma. It tends to come back after surgery and to spread, especially to the lungs, bones and pleura, sometimes many years later (Warmke, Yu and Meis, 2024).

1. Key facts at a glance

Feature Details
Type of cancer Fibroblastic soft-tissue sarcoma
How common Very rare; a few hundred cases reported worldwide
Typical age Adults, median about 45-50 years; children and older people occasionally
Sex Men and women affected about equally
Common sites Deep soft tissue of the thigh, buttock, trunk, shoulder and neck; sometimes bone, kidney or other organs
Key marker MUC4 protein
Usual gene change EWSR1::CREB3L1 fusion; FUS::CREB3L2 in hybrid tumours
Main treatment Wide surgical removal, often with radiotherapy
Outlook Guarded; recurrence and spread are common

2. Causes and risk factors

The cause of SEF is not known. It is not linked to injury, lifestyle or diet, and there is no known inherited form.

Gene changes

Gene change Where it is found Notes
EWSR1::CREB3L1 The most common change in pure SEF Joins two genes to create an abnormal growth signal
FUS::CREB3L2 Hybrid SEF-LGFMS tumours and LGFMS The same fusion found in low-grade fibromyxoid sarcoma
Other EWSR1 or FUS fusions A minority Partners such as CREB3L2 or CREB3L3
YAP1::KMT2A A distinct subgroup, often in bone or with unusual features Described in a small number of tumours (Murshed, Al-Bozom and Ammar, 2021)

These gene changes are found only in the tumour cells. They are not inherited and cannot be passed on.

SEF and low-grade fibromyxoid sarcoma

Feature SEF LGFMS
Main cell type Epithelioid cells in dense collagen Bland spindle cells in fibrous and myxoid tissue
MUC4 staining Positive in most Positive in almost all
Usual fusion EWSR1::CREB3L1 FUS::CREB3L2
Behaviour Aggressive; metastases common Slow, but late relapse is common
Hybrid tumours Share features of both

3. How does it look

To the patient

SEF usually feels like a firm, deep lump that has been present for months or even years. It is often painless at first and can be mistaken for a harmless swelling or a pulled muscle.

During surgery

Feature Description
Shape A rounded or lobulated mass, often with a fairly well-defined edge
Size Commonly 5-10 cm, but from 2 cm to over 20 cm
Cut surface Firm, white-grey and gritty, like scar tissue
Hidden extension Small finger-like spurs into nearby muscle, fat or bone
Bleeding or cysts Uncommon

On scans

On MRI, SEF is often dark on many sequences because of its dense collagen, with patchy enhancement after contrast. CT may show erosion of nearby bone. The appearance is not specific, so a biopsy is always needed.

Under the microscope

Feature Description
Cells Small to medium round cells with clear or pale pink cytoplasm
Pattern Cords, single-file lines, nests and small sheets
Background Very dense, hyalinised (glassy) collagen
Mitoses Often few, which can make the tumour look deceptively bland
Stains MUC4 strongly positive in most; usually negative for keratin, S100 and muscle markers
Molecular test FISH or sequencing to find EWSR1 or FUS rearrangements

Conditions that can look similar

SEF can be mistaken for metastatic carcinoma, lymphoma, sclerosing epithelioid variants of other sarcomas, ossifying fibromyxoid tumour and even scar tissue. Because the tumour is so rare, a specialist sarcoma pathologist should confirm the diagnosis (Warmke, Yu and Meis, 2024).

4. Symptoms

Common symptoms

  • A firm, deep lump, usually in the limbs, trunk or girdle areas
  • A lump that has slowly grown over months or years
  • Pain or tenderness in about a third of people, often as the lump enlarges
  • Stiffness or reduced movement near a joint
  • Numbness or tingling if the tumour presses on a nerve

Symptoms by site

Site Possible symptoms
Thigh, buttock or pelvis Deep ache, limp, swelling
Shoulder or chest wall Pain on movement, visible swelling
Head and neck A lump in the neck or jaw region
Bone Bone pain, fracture after minor injury
Kidney or other organs Pain, blood in the urine, or no symptoms until large

Symptoms of spread

Site of spread Possible symptoms
Lungs Cough, breathlessness, chest pain
Pleura Fluid around the lung, breathlessness
Bone Bone pain, fracture
Lymph nodes Swollen glands
General Tiredness, weight loss

When to seek medical advice

See a doctor about any lump that is larger than about 5 cm, deep in the muscle, growing or painful. Most lumps are harmless, but these features should lead to an ultrasound or MRI and, if needed, referral to a sarcoma centre.

5. Diagnosis

Test Purpose
Ultrasound First check of a lump
MRI Shows the size, depth and relation to nerves, vessels and bone
Core needle biopsy Taken at a sarcoma centre, along the planned surgical route
Immunohistochemistry MUC4 and other stains
Molecular testing Confirms an EWSR1, FUS or other fusion
CT of the chest Looks for lung spread
PET-CT or bone scan Sometimes used to check for spread to bone

Why diagnosis can be delayed

  • The lump often grows slowly and causes little pain
  • Small biopsies may show mainly collagen, which looks like scar
  • The cells may look bland, hiding how aggressive the tumour is
  • The tumour is rare, so many doctors and pathologists never see one

Staging

Like other soft-tissue sarcomas, SEF is staged using the size of the tumour, whether it has reached lymph nodes, and whether it has spread to distant organs. The grade given by the usual sarcoma grading system can be misleading in SEF, because the bland-looking cells may score as low grade even though the tumour behaves aggressively.

Stage group Meaning in simple terms
Localised The tumour is confined to one area and can usually be removed
Locally advanced The tumour involves nerves, major vessels or bone, making surgery more complex
Metastatic The tumour has spread, most often to the lungs, pleura or bone

6. Treatment

Treatment should be planned at a specialist sarcoma centre by a multidisciplinary team.

Surgery

Approach Notes
Wide local excision The main treatment; removes the tumour with a margin of normal tissue
Limb-sparing surgery Preferred in the arms and legs whenever possible
Reconstruction Muscle flaps, grafts or bone reconstruction for large defects
Removal of lung metastases Considered for a small number of lung nodules

Radiotherapy

Radiotherapy can be used ahead of the operation or afterwards to lower the risk of local recurrence, especially when the margins are close. It is also used to relieve pain from metastases.

Drug treatment

Option Notes
Doxorubicin-based chemotherapy Standard first option for advanced sarcoma; SEF responds poorly in many reports
Ifosfamide, gemcitabine, docetaxel or trabectedin Used in later lines with modest benefit
Pazopanib and other targeted drugs Occasional disease control reported
Clinical trials Strongly encouraged, as no drug is known to work reliably

Treatment if SEF comes back or spreads

When SEF returns at the original site, a second operation, sometimes with radiotherapy, can often control it again. When it spreads, the aim is usually to control growth and symptoms for as long as possible:

  • Surgery or precise radiotherapy (stereotactic treatment) for a few slowly growing metastases
  • Drug treatment when there are many metastases or rapid growth
  • Watchful waiting with regular scans when metastases are small and stable, to avoid side effects until treatment is needed
  • Palliative care to manage pain, breathlessness and tiredness alongside other treatment

Side effects

Treatment Possible side effects
Surgery Pain, wound problems, weakness, swelling of a limb
Radiotherapy Skin soreness, tiredness, later stiffness and scarring
Chemotherapy Hair loss, sickness, low blood counts, tiredness, heart effects (doxorubicin)
Targeted drugs Diarrhoea, high blood pressure, liver changes, change in hair colour

What treatment involves day to day

Part of treatment What to expect
Sarcoma surgery Hospital stay of a few days to two weeks
Rehabilitation Physiotherapy for weeks or months after limb surgery
Radiotherapy Daily sessions on weekdays for about 5-6 weeks
Chemotherapy Treatment every 3 weeks, sometimes with short hospital stays

7. Outlook (prognosis)

SEF is regarded as a high-risk sarcoma, even when the cells look bland.

Measure Approximate figures from published series
Local recurrence About half of patients
Distant spread Roughly 50-80% at some point, often to lungs, bone and pleura
Spread present at diagnosis A significant minority
Late relapse Can occur more than 10 years after surgery

Pure SEF behaves more aggressively than hybrid SEF-LGFMS tumours or LGFMS itself (Antonescu et al., 2001; Warmke, Yu and Meis, 2024). Complete removal, smaller size and absence of spread at diagnosis are linked with better results. Some people live for many years with slowly growing metastases.

Research and future treatments

Because SEF is driven by a single gene fusion in most cases, researchers are studying how the abnormal CREB3L1 protein drives tumour growth and whether it can be blocked. Laboratory models made from patients’ tumours are helping to test new drug combinations (Woods et al., 2021). International sarcoma groups are also pooling cases so that treatment results can be compared across many centres.

8. Follow-up

Follow-up Purpose
Clinic visits every 3-6 months at first Examination of the scar and surrounding area
MRI of the original site Detects local recurrence
CT of the chest Detects lung spread
Long-term follow-up for 10 years or more Because late relapse is typical

9. Living with sclerosing epithelioid fibrosarcoma

  • Keep a long-term follow-up plan, even after many years without problems
  • Report any new lump, pain or cough without waiting for the next appointment
  • Continue physiotherapy to keep strength and movement after surgery
  • Ask about lymphoedema care if a limb swells after treatment
  • Ask about clinical trials for rare sarcomas
  • Seek support from sarcoma charities, specialist nurses and patient groups

10. Frequently asked questions

Question Answer
Is SEF the same as fibrosarcoma? No. It is a distinct sarcoma with its own markers and gene changes
Is it inherited? No
Why do the doctors call it aggressive when it grew so slowly? Despite slow growth, SEF often comes back and spreads over time
Will I need chemotherapy? Not usually for localised disease; it is mainly used if the cancer spreads
How long will I be followed up? Usually for at least 10 years
Can children get SEF? Rarely, yes

11. Questions to ask your care team

  • Is this pure SEF or a hybrid with LGFMS?
  • Which gene fusion does my tumour have?
  • Were the margins clear after surgery?
  • Do I need radiotherapy?
  • How often will I have scans, and of which areas?
  • Are there clinical trials I could join?

Resources

  1. Antonescu, C.R. et al. (2001) ‘Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor’, American Journal of Surgical Pathology, 25(6), pp. 699-709.
  2. Doyle, L.A. et al. (2012) ‘MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement’, American Journal of Surgical Pathology, 36(10), pp. 1444-1451.
  3. Murshed, K.A., Al-Bozom, I. and Ammar, A. (2021) ‘Sclerosing epithelioid fibrosarcoma: in-depth review of a genetically heterogeneous tumor’, APMIS, 129(8), pp. 455-460.
  4. Warmke, L.M., Yu, W. and Meis, J.M. (2024) ‘Sclerosing epithelioid fibrosarcoma’, Surgical Pathology Clinics, 17(1), pp. 119-139.
  5. Woods, A.D. et al. (2021) ‘Metastatic pediatric sclerosing epithelioid fibrosarcoma’, Cold Spring Harbor Molecular Case Studies, 7(5), a006093.
  6. National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.